NEWS

NEWS

Connecta Therapeutics drug for fragile X syndrome receives orphan designation from European Medicines Agency

September 07, 2021

CTH120, designed using artificial intelligence techniques, will start Phase I in 2022. CTH120 designation as orphan drug validates and empowers Connecta Therapeutics's strategy in neurodevelopmental diseases.

Connecta Therapeutics, the CRG and the IMIM join forces to develop an innovative treatment for fragile X syndrome

December 01, 2020

The public-private consortium has obtained a grant of €1.97 million from the Spanish National Innovation Agency. Preclinical studies have shown that the CTH120 molecule can modulate neuroplasticity, the ability of cells of the nervous system to regenerate in response to pathological influences.

Connecta Therapeutics, the CRG and the IMIM receive €1.97 million from the Spanish National Innovation Agency to develop a treatment for fragile X syndrome

December 01, 2020

The public-private consortium has earned this grant through the 2019 “Collaboration Challenges” programme

CONNECTA THERAPEUTICS RAISES €1.7 M TO DEVELOP NEW TREATMENT FOR FRAGILE X SYNDROME

September 26, 2020

Connecta Therapeutics has closed a €1.7million round of investment led by Inveready that will allow the company to take its first drug through to phase IIa clinical trials in patients who have fragile X syndrome (FXS). CDTI and the biotechnology company’s founders also participated.

« Previous 1 2

NEWS

Connecta Therapeutics drug for fragile X syndrome receives orphan designation from European Medicines Agency

Connecta Therapeutics, the CRG and the IMIM join forces to develop an innovative treatment for fragile X syndrome

Connecta Therapeutics, the CRG and the IMIM receive €1.97 million from the Spanish National Innovation Agency to develop a treatment for fragile X syndrome

CONNECTA THERAPEUTICS RAISES €1.7 M TO DEVELOP NEW TREATMENT FOR FRAGILE X SYNDROME

CONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Syndrome Program

CONNECTA Therapeutics and Centre for Genomic Regulation to Present First-in-Class Program CTH120 for Fragile X Syndrome at FENS Forum 2026

CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome

CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome with EIC Accelerator Support

CONNECTA Therapeutics announces positive results from Phase I study of neurodevelopmental disorders drug candidate, CTH120